We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 29

The competition and IP intersect

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • February 13 2014

In a move which will be closely watched by the pharmaceutical industry, the ACCC has commenced proceedings against Pfizer alleging breaches of the

Penalties for unconscious breaches of the Trade Practices Act

  • PwC Australia
  • -
  • Australia
  • -
  • September 14 2010

On 27 August 2010, the Federal Court ordered Baxter Healthcare Pty Ltd (Baxter) to pay penalties of $4.9 million in respect of contraventions of sections 46(1)(c) and 47(1) of the Trade Practices Act (1974) (the TPA

ACCC conditionally clears NestlePfizer deal

  • Herbert Smith Freehills LLP
  • -
  • Australia
  • -
  • November 30 2012

On 22 November 2012, the Australian Competition and Consumer Commission (ACCC) announced it would not oppose the proposal by Nestlé SA to acquire the global infant nutrition business of Pfizer Inc (the transaction), subject to court enforceable undertakings

Competition regulators continue their campaign against pharmaceutical companies

  • King & Wood Mallesons
  • -
  • Australia, USA
  • -
  • June 1 2011

Last month, the US Federal Trade Commission (FTC) released its findings on reverse payment settlements between pharmaceutical companies in the 2010 US fiscal year

ACCC joins NRM to Advanced Medical Institute proceedings, alleging unfair contract terms

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • November 3 2011

On 7 September 2011, the ACCC announced that the Federal Court had granted orders to add NRM Corporation Pty Ltd and NRM Trading Pty Ltd as respondents in the ACCC’s existing case against Advanced Medical Institute for alleged unconscionable conduct

European Commission ups the cost of paying for delay

  • King & Wood Mallesons
  • -
  • Australia, European Union, USA
  • -
  • August 13 2012

On 25 July 2012, the EC alleged that Danish pharmaceutical company Lundbeck violated EU antitrust rules by colluding to prevent other pharma companies from marketing generic versions of its best-seller antidepressant, citalopram

Sharing is caring

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • June 21 2013

In its consideration of the latest in a string of authorisation applications made in the medical industry to collectively bargain on fee arrangements

ACCC proposes to allow GPs to set practice prices

  • Gilbert + Tobin
  • -
  • Australia
  • -
  • February 28 2013

In response to an application lodged by the Australian Medical Association, the ACCC proposes to allow GPs in single practices to set practice prices

GPs given a clean bill of health to engage in price setting

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • March 18 2013

The ACCC has granted authorisation to individual General Practitioners (GPs) working in shared practices to allow them to engage in intra-practice

Collective bargaining

  • Gilbert + Tobin
  • -
  • Australia
  • -
  • August 22 2012

The ACCC proposes to allow St Vincent’s Private Hospital Sydney to join other members of the St Vincent’s Health Australia Group (these other members being related bodies corporate) in the collective and joint activity of the group, effectively enabling them to operate as a single economic entity